Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 5, 2007, Pages 1448-1455

  Bernal, Patricia ^a   Raoul, Jean Luc ^b   Vidmar, Gaj ^c   Sereegotov, Erdenechimeg ^d   Sundram, Felix X ^e   Kumar, Ajay ^f   Jeong, Jae Min ^g   Pusuwan, Pawana ^h   Divgi, Chaitanya ^i,j   Zanzonico, Pat ⁱ   Stare, Janez ^c   Buscombe, John ^k   Minh, Chau Trinh Thi ^l   Saw, Maung Maung ^e   Chen, Shaoliang ^m   Ogbac, Ruben ⁿ   Padhy, Ajit K ^e,o  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^g Seoul National University Hospital   (South Korea)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k ROYAL FREE HOSPITAL   (United Kingdom)

^l CHO RAY HOSPITAL   (Viet Nam)

^m FUDAN UNIVERSITY   (China)

ⁿ St Luke's Medical Centre   (Philippines)

^o INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

more..

Author keywords

188 Rhenium; Hepatocellular carcinoma; Internal radiotherapy; Radiolabeled lipiodol

Indexed keywords

HEPATOCELLULAR CARCINOMA; INTERNAL RADIOTHERAPY; RADIOLABELED LIPIODOL;

BIOLOGICAL ORGANS; DRUG DOSAGE; RADIOTHERAPY;

ONCOLOGY;

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; IODINATED POPPYSEED OIL I 131; LIPIODOL RE 188; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER GROWTH; CANCER OF THE LIVER ITALIAN PROGRAM SCORE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPOTENSION; INOPERABLE CANCER; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION PROTECTION; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIOISOTOPES; REGRESSION ANALYSIS; REMISSION INDUCTION; RHENIUM; STATISTICS, NONPARAMETRIC;

EID: 36148934869     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.009     Document Type: Article

References (26)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359 (2002) 1734-1739
3. Raoul J.L., Guyader D., Bretagne J.F., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35 (1994) 1782-1787
4. Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26 (1997) 1156-1161
5. 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med 45 (2004) 612-618
6. Lee Y.S., Jeong J.M., Kim Y.J., et al. Synthesis of 188Re labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Comm 23 (2002) 237-242
7. Paeng J.C., Jeong J.M., Yoon C.L., et al. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: Preclinical study to rabbit live cancer model. J Nucl Med 44 (2003) 2033-2038
8. Lambert B., Bacher K., De Keukeleire K., et al. 188Re-HDD/Lipiodol for treatment of hepatocellular carcinoma: A feasibility study in patients with advanced cirrhosis. J Nucl Med 46 (2005) 1326-1332
9. Sundram F., Chau T.C., Onkhuudai P., et al. Preliminary results of transarterial rhenium-188 lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 250-257
10. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 28 (1998) 751-755
11. Guhlke S., Beets A.L., Mirzadeh S., et al. Tandem cation/anion column treatment of ammonium acetate eluants of the alumina-based tungsten-188/rhenium-188 generator: A new simple method for effective concentration of rhenium-188 prephenate solutions. J Nucl Med 41 (2000) 1271-1278
12. Knapp FF Jr., (Russ), Turner JH, Jeong J-M, et al. Issues associated with the use of tungsten-188/rhenium-188 generator and concentrator system and preparation of Re-188 HDD: A report. World J Nucl Med 2004;3:137-143.
13. Jeong J.M., Kim Y.J., Lee Y.S., et al. Lipiodol solution of a lipophilic agent, 188ReTDD, for the treatment of liver cancer. Nucl Med Biol 28 (2001) 197-204
14. Lo C.M., Ngan H., Tso W.K., et al. Randomised controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
15. Salem R., and Thurston K.G. Radioembolization with 90Yttrium microspheres: A state of the art brachytherapy treatment for primary and secondary liver malignancies. J Vasc Interv Radiol 17 (2006) 1251-1278
16. Bruix J., and Llovet J.M. Prognostic prediction and treatment strategies in hepatocellular carcinoma. Hepatology 35 (2002) 519-524
17. The Cancer of the Liver Italian Program (CLIP) investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31 (2000) 840-845
18. Leung D.A., Goin J.E., Sickles C., Raskay B.J., and Soulen M.C. Determinants of postembolization syndrome after hepatic chemoembilization. J Vasc Interv Radiol 12 (2001) 321-326
19. Raoul J.L., Boucher E., Olivie D., et al. Association of cisplatin and intra-arterial injection of (131)I-lipiodol in treatment of hepatocellular carcinoma: Results of a phase II trial. Int J Radiat Oncol Biol Phys 64 (2006) 745-750
20. Leung T.W., Lau W.Y., Ho S.K., et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33 (1995) 919-924
21. Raoul J.L., Bretagne J.F., Caucanas P., et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled-lipiodol. Cancer 69 (1992) 346-352
22. Raoul J.L., Bourguet P., Bretagne J.F., et al. Hepatic artery injection of I131 labelled lipiodol. I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 168 (1988) 541-545
23. Ryder S.D., Rizzi P.M., Metivier E., et al. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma. Gut 38 (1996) 125-128
24. Raoul J.L., Messner M., Boucher E., et al. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled Lipiodol. Br J Surg 90 (2003) 1379-1383
25. Geschwind J.F.H., Ramsey D.E., Choti M.A., et al. Chemoembolization of hepatocellular carcinoma. Results of a meta-analysis. Am J Clin Oncol 26 (2003) 344-349
26. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359 (2002) 1734-1739